CircoFLEX

BOEHRINGER INGELHEIM SUPPORTS VETERINARY MENTAL WELLNESS WITH $225,000 SPONSORSHIP OF THE VETERINARY HOPE FOUNDATION (VHF)

Retrieved on: 
Monday, October 10, 2022
LinkedIn, Suicide, Veterinarian, Work, Therapy, VMX, Horse, American Veterinary Medical Association, Animal, Education, GA, Ivermectin, Health, VHF, Twitter, Instagram, Program, SE, PETS, Boehringer Ingelheim Animal Health, Partnership, CircoFLEX, Boehringer Ingelheim, Awareness, Akwa Ibom State Association of Nigeria, USA Inc., A Glimmer of Hope Foundation, Afoxolaner, Grief, Pyramid, Human, Livestock, Veterinary medicine, Medicine, Fine chemical, Facebook

The Veterinary Hope Foundation's support groups provide veterinary professionals--who are three times more likely1 than the general population to die by suicide--with early intervention efforts and allow them to connect in a safe, confidential and caring space. These groups, led by a licensed mental health professional, focus on topics meaningful to practicing veterinarians and their teams such as communicating with troubled clients, balancing family and work, handling grief and cultivating emotional resilience.

Key Points: 
  • DULUTH, Ga., Oct. 10, 2022 /PRNewswire/ -- Boehringer Ingelheim Animal Health USA Inc. is honored to support the Veterinary Hope Foundation (VHF) with a $225,000 sponsorship.
  • With this contribution, Boehringer Ingelheim becomes a founding sponsor of the Veterinary Hope Foundation.
  • In addition to the sponsorship, Boehringer Ingelheim will advocate and share VHF's mission as their teams visit veterinary clinics across the country.
  • Boehringer Ingelheim continued to elevate VHF's mission during the 2022 Veterinary Meeting & Expo (VMX), the world's largest veterinary conference, held Jan. 15-19.

POULTRY VACCINE MANUFACTURING FACILITY BECOMES FIRST BOEHRINGER INGELHEIM ANIMAL HEALTH SITE IN THE U.S. TO BE CERTIFIED AS CARBON NEUTRAL

Retrieved on: 
Friday, April 22, 2022
Electron energy loss spectroscopy, Corporation, Veterinarian, Replacement, Carbon, Uniloc USA, Inc. v. Microsoft Corp., Steam, Afoxolaner, CircoFLEX, Natural gas, United Nations Sustainable Development Group, Ivermectin, Health, Boehringer Ingelheim, Human, Georgia Power, Therapy, Goal, Livestock, Electricity, Review, Environment, PETS, Animal, Poultry, Boehringer Ingelheim Animal Health, Wind, Certification, Partnership, Horse, Miniature pig, Sustainable development, Renewable energy, Fine chemical, Generation (disambiguation)

DULUTH, Ga., April 22, 2022 /PRNewswire/ -- Boehringer Ingelheim U.S. Animal Health today announced that its poultry vaccine site in Gainesville, Ga., has received carbon neutral certification, the first of its U.S. sites to earn this designation. The site, which produces nearly 60 billion poultry vaccines every year, is Boehringer Ingelheim's first major manufacturing facility site in the U.S. and its third site globally to become carbon neutral.

Key Points: 
  • Gainesville, Ga. poultry vaccine site has received carbon neutrality certification, becoming the company's first U.S. animal health manufacturing plant to announce carbon neutrality
    DULUTH, Ga., April 22, 2022 /PRNewswire/ -- Boehringer Ingelheim U.S.
  • Animal Health today announced that its poultry vaccine site in Gainesville, Ga., has received carbon neutral certification, the first of its U.S. sites to earn this designation.
  • The site, which produces nearly 60 billion poultry vaccines every year, is Boehringer Ingelheim's first major manufacturing facility site in the U.S. and its third site globally to become carbon neutral.
  • "This move to carbon neutrality helps protect the environment we live in," said Lara Sheeley, head of the U.S. swine and poultry divisions at Boehringer Ingelheim Animal Health.

Boehringer Ingelheim Appoints General Manager of Pawru, Inc.

Retrieved on: 
Wednesday, July 14, 2021
Boehringer Ingelheim, Pharmaceutical companies, Boehringer, Ingelheim am Rhein, Economy of Germany, States of Germany, CircoFLEX

DULUTH, Ga., July 14, 2021 /PRNewswire/ -- Boehringer Ingelheim Animal Health USA Inc. has appointed Bryan Haardt as General Manager of Pawru, Inc., a Boehringer Ingelheim companythat facilitates collaborative pet care by connecting veterinary professionals and pet owners on an innovative digital platform.

Key Points: 
  • DULUTH, Ga., July 14, 2021 /PRNewswire/ -- Boehringer Ingelheim Animal Health USA Inc. has appointed Bryan Haardt as General Manager of Pawru, Inc., a Boehringer Ingelheim companythat facilitates collaborative pet care by connecting veterinary professionals and pet owners on an innovative digital platform.
  • Boehringer Ingelheim announced this year that it had created Pawru as a separate company and would re-brand a service that the company offered nationwide in 2020 as PetPro Connect.
  • Since its founding in 1885, Boehringer Ingelheim has been independent and family owned.
  • In 2020, Boehringer Ingelheim achieved net sales of around $22.33 billion (19.57 billion euros).

Global Veterinary Vaccines Industry (2020 to 2025) - Technological Advancements Present Lucrative Opportunities - ResearchAndMarkets.com

Retrieved on: 
Monday, May 25, 2020
Veterinary, Health, Vaccination, Vaccine, Virology, Vaccines, Medical specialties, Medicine, RTT, Branches of biology, CircoFLEX

The global veterinary vaccines market is projected to reach USD 11,337.5 million by 2025 from USD 8,014.2 million in 2020, at a CAGR of 7.2% from 2020 to 2025.

Key Points: 
  • The global veterinary vaccines market is projected to reach USD 11,337.5 million by 2025 from USD 8,014.2 million in 2020, at a CAGR of 7.2% from 2020 to 2025.
  • Based on technology, the veterinary vaccines market is segmented into live attenuated vaccines, inactivated vaccines, toxoid vaccines, recombinant vaccines, and other vaccines.
  • By type, the porcine vaccines segment dominated the veterinary vaccines market in 2019.
  • Based on type, the veterinary vaccines market is segmented porcine vaccines, poultry vaccines, livestock vaccines, companion animal vaccines, aquaculture vaccines, and other animal vaccines.

Insilico enters into a research collaboration with Boehringer Ingelheim to apply novel generative artificial intelligence system for discovery of potential therapeutic targets

Retrieved on: 
Tuesday, April 14, 2020
Health, States of Germany, Boehringer, Ingelheim am Rhein, Boehringer Ingelheim, Pharmaceutical industry, Merial, CircoFLEX

Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim.

Key Points: 
  • Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim.
  • In animal health, Boehringer Ingelheim stands for advanced prevention.
  • Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry's top 20 companies.
  • Boehringer Ingelheim Innovation Prize is part of Boehringer Ingelheim Partnering Day.

Boehringer Ingelheim Chooses Docuvera® Structured Content Management to Drive Efficiency in Pharmaceutical Documentation

Retrieved on: 
Thursday, January 30, 2020
Technology, Publishing, Office Products, Communications, Software, Biotechnology, Health, Pharmaceutical, Retail, Boehringer, Health, Ingelheim am Rhein, States of Germany, Pharmaceutical industry, Boehringer Ingelheim, CircoFLEX

Author-it Software Corporation today announced that the pharmaceutical company Boehringer Ingelheim selected Docuvera to enable medical authors to efficiently build clinical and regulatory documents from pre-approved components of medical content.

Key Points: 
  • Author-it Software Corporation today announced that the pharmaceutical company Boehringer Ingelheim selected Docuvera to enable medical authors to efficiently build clinical and regulatory documents from pre-approved components of medical content.
  • Docuvera gives Boehringer Ingelheim a powerful, yet intuitive platform for authors to create and update pharmaceutical documentation in a fraction of the time versus traditional desktop software.
  • Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim.
  • Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industrys top 20 companies.

Boehringer Ingelheim and GNA Biosolutions partner on emergency veterinary diagnostics development

Retrieved on: 
Tuesday, February 26, 2019
Health, Biotechnology, Clinical trials, Infectious diseases, Medical devices, Pharmaceutical, Veterinary, Boehringer Ingelheim, Boehringer, Health, Ingelheim am Rhein, Pharmaceutical industry, Pharmaceutical sciences, Education in Vienna, CircoFLEX, Merial

Boehringer Ingelheim and GNA Biosolutions announce that they have entered into a research collaboration focused on the development of a rapid African swine fever (ASF) diagnostic test.

Key Points: 
  • Boehringer Ingelheim and GNA Biosolutions announce that they have entered into a research collaboration focused on the development of a rapid African swine fever (ASF) diagnostic test.
  • We are delighted to enter this collaboration with Boehringer Ingelheim, a global leader in animal health.
  • Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim.
  • As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success, rather than short-term profit.